Clinical trialPhase 1 / Phase 2Completed
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Outcome
- Finished, no results posted
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 3 March 2023
- Ended
- 18 December 2025
- Enrollment
- 40 participants
- Sites
- 7
- Primary outcomes
- Adverse Events; AEs related to study drug; Recommended Phase 2 dose (RP2D) or maximum tolerated dose (MTD)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 5 October 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors. The study included dose escalation and planned dose expansion phases. Only the dose escalation phases were conducted. The planned dose expansion phase were not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern. The study sought to assess the safety of KVA12123 \[TBS-2025\] given alone or with pembrolizumab and to identify appropriate doses for future clinical trials. Participants in the doses for future clinical trials. Participants in the dose escalation phases visited study sites for treatment and safety assessments. These assessments included blood samples, imaging scans, physical examinations, and heart function tests.
Detailed description public domain (ClinicalTrials.gov)
This was a first-in-human (FIH), Phase 1/2, open-label, multicenter, dose escalation, and dose expansion study designed to evaluate the safety, tolerability, PK, immunogenicity, and tumor response of the investigational drug KVA12123, subsequently designated TBS-2025, alone and in combination with pembrolizumab in adults with relapsed or refractory advanced solid tumors. The study was planned to conduct in 4 planned parts: Parts A and B focus on dose escalation (single-agent and in combination), and Parts C and D focus on dose expansion (single-agent and in combination). Parts A (single-agent KVA12123) and B (KVA12123 + pembrolizumab) allowed up to 10 dose escalation cohorts: 6 in Part A and 4 in Part B, with 1 to 6 participants per cohorts. These parts were intended to characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary tumor response, and to inform the selection of recommended phase 2 doses. Parts C (single-agent KVA12123) and D (KVA12123 + pembrolizumab) were planned but not initiated following a business decision to discontinue development in solid tumors. This decision was unrelated to any identified safety concern.